It is currently in Phase 3 trials and is expected to be commercially available in late 2026 or 2027
Prevents lipohypertrophy and injection-site fatigue
If you are taking other medications, especially for chronic diseases like diabetes, always consult your doctor before combining semaglutide
Hypoglycaemia may occur when used with insulin or sulfonylureas
Olesen Synthesis/1949 Director, Drug Safety Operations International Product Manager, MEQU/1947 Senior Safety Manager Global Clinical Lead, Clinical Development, Migraine & Pain Rdgiver og forhandler med flair for pipeline og partnerskaber (Pipeline Insights & Engagement Advisor) - vil du vre med til at sikre fremtidens adgang til nye lgemidler
Compared to eating out, which becomes less appealing anyway on GLP-1 therapy, this is significantly cheaper and infinitely more aligned with your health goals